On the one hand, the liver is the primary site of clotting-factor synthesis and as revealed by a single-center cohort study, NAFLD severity is independently responsible for the elevation of plasminogen activator inhibitor-1 (PAI-1) levels [44]. The gene discussed is SERPINE1; the disease is metabolic dysfunction-associated steatotic liver disease.